This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.






Fig. 1




Fig. 2




Fig. 3





Fig. 4

Sca 1


Anti-E1 levels in NON-responders to IFN treatment




weeks after start of treatment Fig. 5

エタ ∑ ¥ 0 80 2 Anti-E1 levels in RESPONDERS to IFN treatment 9 50 weeks after start of treatment 40 Fig. 6 SERIES 1 30 20 0 FN SNS 01. 7 0 9 ω 20 12

Anti-E1 levels in patients with COMPLETE response to IFN




Anti-E1 levels in INCOMPLETE responders to IFN treatment



months after start of treatment Fig. 8



Anti-E2 levels in NON-RESPONDERS to IFN treatment




weeks after start of treatment Fig. 9


dl M ★ ◆ O 3a al H P 1b 80 50 55 60 65 70 75 Anti-E2 levels in RESPONDERS to IFN treatment weeks after start of treatment 10 15 20 25 30 35 40 45 SERIES 1 Fig. 10 <u>H</u> 2 0 Ş N/S 0 9 0 ထ V 20 14 12


The same of the sa

Anti-E2 levels in INCOMPLETE responders to IFN treatment




Anti-E2 levels in COMPLETE responders to IFN treatment





Competition of reactivity of anti-E1 Mabs with peptides



Anti-E1 (epitope 1) levels in NON-RESPONDERS to IFN treatment




Fig.15

dl M ★ • O 3a P 1b Anti-E1 (epitope 1) levels in RESPONDERS to IFN treatment 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 weeks after start of treatment Fig. 16 SERIES 1 EZ Z 5 N/S 20 8 9 2

Anti-E1 (epitope 2) levels in NON-RESPONDERS to IFN treatment





Fig.17

Anti-E1 (epitope 2) levels in RESPONDERS to IFN treatment






Fig.19




Fig. 20



Fig. 21A

5' GGCATGCAAGCTTAATTAATT3' (SEQ ID NO 1)
3'ACGTCCGTACGTTCGAATTAATTAATCGA5' (SEQ ID NO 94)

SEQ ID NO 3 (HCCI9A)

SEQ ID NO 5 (HCCI10A)

Fig. 21B

SEQ ID NO 7 (HCCI11A)

SEQ ID NO 9 (HCCI12A)

SEQ ID NO 11 (HCCI13A)

Fig. 21C

GCCCTGCGTTCGGGAGGGCAACTCCTCCCGTTGCTGGGTGGCGCTCACTCCCACGCTC
GCGGCCAGGAACGCCAGCGTCCCCACAACGACAATACGACGCCACGTCGATTTGCTC
GTTGGGGCTGCTGCTTCTGTTCCGCTATGTACGTGGGGGATCTCTGCGGATCTGTTT
CCTTGTTTCCCAGCTGTTCACCTTCTCACCTCGCCGGCATCAAACAGTACAGGACTGCA
ACTGCTCAATCTATCCCGGCCATGTATCAGGTCACCGCATGGCTTGGGATATGATGAT
GAACTGGTAATAG

SEQ ID NO 13 (HCCI17A)

SEQ ID NO 15 (HCPr51)
ATGCCCGGTTGCTCTTTCTCTATCTT

SEQ ID NO 16 (HCPr52)

ATGTTGGGTAAGGTCATCGATACCCT

SEQ ID NO 17 (HCPr53)
CTATTAGGACCAGTTCATCATCATATCCCA

SEQ ID NO 18 (HCPr54)
CTATTACCAGTTCATCATCATATCCCA

SEQ ID NO 19 (HCPr107)
ATACGACGCCACGTCGATTCCCAGCTGTTCACCATC

Fig. 21D

SEQ ID NO 20 (HCPr108)
GATGGTGAACAGCTGGGAATCGACGTGGCGTCGTAT

SEQ ID NO 21 (HCCI37)

SEQ ID NO 23 (HCCI38)

SEQ ID NO 25 (HCC139)

ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT

Fig. 21E

ATCTTCCTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG
CAACGTGTCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTAT
GAGGCAGCGGACATGATCATGCACACCCCCGGGTGCCCTGCGTTCGGGAGAAC
AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG
TCCCCACCACGACAATACGACGCCACGTCGATTCCCAGCTGTTCACCATCTCGCCTCG
CCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGT
CACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTAT
CGCAGCTGCTCCGGATCCTCTAATAG

SEQ ID NO 27 (HCC!40)

SEQ ID NO 29 (HCC162)

ATGGGTAAGGTCATCGATACCCTTACGTGCGGATCTCGCCGATCTCATGGGGTACATCC
CGCTCGTCGGCGCTCCCGTAGGAGGCGTCGCAAGAGCCCTTGCGCATGGCGTGAGGGC
CCTTGAAGACGGGATAAATTTCGCAACAGGGAATTTGCCCGGTTGCTCCTTTTCTATTT
TCCTTCTCGCTCTGTTCTCTTGCTTAATTCATCCAGCAGCTAGTCTAGAGTGGCGGAAT
ACGTCTGGCCTCTATGTCCTTACCAACGACTGTTCCAATAGCAGTATTGTGTACGAGGC
CGATGACGTTATTCTGCACCACCCGGCTGCATACCTTGTGTCCAGGACGGCAATACA
TCCACGTGCTGGACCCCAGTGACACCTACAGTGGCAGTCAAGTACGTCGGAGCAACCA
CCGCTTCGATACGCAGTCATGTGGACCTATTAGTGGGCGCGCCACGATGTGCTCTGC
GCTCTACGTGGGTGACATGTGGGGCTGTCTTCCTCGTGGGACAAGCCTTCACGTTCA
GACCTCGTCGCCCATCAAACGGTCCAGACCTGTAACTGCTCGCTGTACCCAGGCCATCT
TTCAGGACATCGAATGGCTTGGGGATATGATGATGAACTGGTAATAG

Fig. 21F

SEQ ID NO 31 (HCCl63)

ATGGGTAAGGTCATCGATACCCTAACGTGCGGATCTCACGGGGTATATCC
CGCTCGTAGGCGCCCCATTGGGGGGCGTCGCAAGGGCTCTCGCACACGGTGTGAGGGT
CCTTGAGGACGGGGTAAACTATGCAACAGGGAATTTACCCGGTTGCTCTTTCTCTATCT
TTATTCTTGCTCTTCTCTCTGTGTCTGACCGTTCCGGCCTCTGCAGTTCCCTACCGAAATG
CCTCTGGGATTTATCATGTTACCAATGATTGCCCAAACTCTTCCATAGTCTATGAGGCA
GATAACCTGATCCTACACGCACCTGGTTGCGTGCCTTGTGTCATGACAGGTAATGTGA
GTAGATGCTGGGTCCAAATTACCCCTACACTGTCAGCCCCGAGCCTCGGAGCAGTCAC
GGCTCCTCTTCGGAGAGCCGTTGACTACCTAGCGGGAGGGGCTGCCCTCTGCTCCGCG
TTATACGTAGGAGACGCGTGGGGGCACTATTCTTGGTAGGCCAAATGTTCACCTATA
GGCCTCGCCAGCACGCTACGGTGCAGAACTGCAACTGTTCCATTTACAGTGGCCATGT
TACCGGCCACCGGATGGCATGGGGATATGATGATGAACTGGTAATAG

SEQ ID NO 33 (HCPr109)
TGGGATATGATGATGAACTGGTC

SEQ ID NO 34 (HCPr72)
CTATTATGGTGGTAAKGCCARCARGAGCAGGAG

SEQ ID NO 35 (HCCL22A)

Fig. 21G

CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAĞĞTÜ
TAGGATGTACGTGGGGGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCG
AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTG
TCTACAACAGAGTGGCAGATACTGCCCTGTTCCTTCACCACCCTGCCGGCCCTATCCA
CCGGCCTGATCCACCTCCATCAGAACATCGTGGACGTGCAATACCTGTACGGTGTAGG
GTCGGCGGTTGTCTCCCTTGTCATCAAATGGGAGTATGTCCTGTTGCTCTTCCTT
GGCAGACGCGCGCATCTGCGCCTGCTTATGGATGATGCTGATAGCTCAAGCTGAG
GCCGCCTTAGAGAACCTGGTGGTCCTCAATGCGGCGGCCGTGGCCGGGGCGCATGGC
ACTCTTTCCTTCCTTGTGTTCTTCTTGTGCTGCCTGGTACATCAAGGGCAGGCTGGTCCC
TGGTGCGGCATACGCCTTCTATGGCGTGGCCGCTGCTCCTGCTTCTGCTGCCTTAC
CACCACGAGCTTATGCCTAGTAA

SEQ ID NO 37 (HCCI41)

GATCCCACAAGCTGTCGTGGACATGGTGGCGGGGCCCATTGGGGAGTCCTGGCGG CCTCGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCT TTGCCGGCGTCGACGGGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCA GGGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACAC AGGGTTCTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAG CGCTTGGCCAGCTGTCGCTCCATCGACAGTTCGCTCAGGGGTGGGGTCCCCTCACTT ACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCCTCGACC GTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCC CTGTTGTGGTGGGGACGACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGGCGAA CGACTCGGATGTGCTGATTCTCAACACACGCGGCCGCCGCGAGGCAACTGGTTCGGC TGTACATGGATGAATGGCACTGGGTTCACCAAGACGTGTGGGGGGCCCCCCGTGCAACA CGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTT CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT TAGGATGTACGTGGGGGGCGTGGAGCCACAGGTTCGAAGCCGCATGCAATTGGACTCG AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTG

SEQ ID NO 39 (HCC142)

GATCCCACAAGCTGTCGTGGACATGGTGGCGGGGCCCATTGGGGAGTCCTGGCGGGCCCCCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCT

Fig. 21H

TTGCCGGCGTCGACGGGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCA; GGGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACAC AGGGTTCTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAG CGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTT ACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACC GTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCC CTGTTGTGGTGGGGGGGGGCGAA CGACTCGGATGTGCTGATTCTCAACACGCGGCGGCCGCCGCGAGGCAACTGGTTCGGC TGTACATGGATGAATGGCACTGGGTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACA CGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTT CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT TAGGATGTACGTGGGGGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCG AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTG TCTACAACAGGTGATCGAGGGCAGACACCATCACCACCATCACTAATAG

SEQ ID NO 41 (HCCI43)

ATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACG GGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCT CTTTAGCCCCGGGTCGGCTCAGAAATCCAGCTCGTAAACACCAACGGCAGTTGGCAC ATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCAC TATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCG CTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGC TCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCG CGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGAC ATTCTCAACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATG GCACTGGGTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCA ACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGC CAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGG CTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGG GGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGA CTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGAGTGG CAGAGCTTAATTAATTAG

Fig. 21I

SEQ ID NO 43 (HCCI44)

ATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACG GGCATACCCGCGTGTCAGGAGGGCCAGCCAGCCTCCGATACCAGGGGCCTTGTGTCCCT CTTTAGCCCCGGGTCGGCTCAGAAATCCAGCTCGTAAACACCAACGGCAGTTGGCAC ATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCAC TATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCG CTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGC TCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCG CGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGAC GACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGGCGAACGACTCGGATGTGCTG ATTCTCAACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATG GCACTGGGTTCACCAAGACGTGTGGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCA ACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGC CAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGG CTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGG GGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGA CTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGGTGAT CGAGGGCAGACACCATCACCATCACTAATAG

SEQ ID NO 45 (HCCL6+)

Fig. 21J

SEQ ID NO 47 (HCC!65)

AATTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA TTCCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG GGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT ATCTTCCTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG CAACGTGTCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAÁGCATTGTGTAT AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG TCCCCACCACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGCGGCTGCTTTCTG TTCCGCTATGTACGTGGGGGACCTCTGCGGATCTGTCTTCCTCGTCTCCCAGCTGTTCA CCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGG CCACATAACGGGTCACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTACAACG GCCCTGGTGGTATCGCAGCTGCTCCGGATCCCACAAGCTGTCGTGGACATGGTGGCGG GGGCCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGGGGAACTGGGC TAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGGGCATACCCGCGTGTCAG GAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGC TCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAACAGGACTGCCCT GAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCTACAAACACAAA TTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCG CTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGGCCCTA CTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGT CCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTTTGGTGT CCCCACGTATAACTGGGGGGGGGAACGACTCGGATGTGCTGATTCTCAACAACACGCGG CCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTCACCAAGA CGTGTGGGGGCCCCCGTGCAACATCGGGGGGGCCGGCAACAACACCTTGACCTGCC

Fig. 21K


SEQ ID NO 49 (HCCl66)

ATGAGCACGAATCCTAAACCTCAAAGAAAAACCAAACGTAACACCAACCGCCGCCCA CAGGACGTCAAGTTCCCGGGCGGTGGTCAGATCGTTGGTGGAGTTTACCTGTTGCCGC GCAGGGCCCCAGGTTGGGTGTGCGCGCGACTAGGAAGACTTCCGAGCGGTCGCAAC CTCGTGGGAGGCGACAACCTATCCCCAAGGCTCGCCGACCCGAGGGTAGGGCCTGGG CTCAGCCGGGTACCCTTGGCCCCTCTATGGCAATGAGGGCATGGGGTGGGCAGGATG GCTCCTGTCACCCCGCGGCTCTCGGCCTAGTTGGGGCCCTACAGACCCCCGGCGTAGG TCGCGTAATTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGG GGTACATTCCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCCTGGCGCATGG CGTCCGGGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCT TTCTCTATCTTCCTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAA GTGCGCAACGTGTCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTG GAACAACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCC AGCGTCCCCACCACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGCGGCTGCTT TCTGTTCCGCTATGTACGTGGGGGACCTCTGCGGATCTGTCTTCCTCGTCTCCCAGCTG TTCACCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATC CCGGCCACATAACGGGTCACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTAC AACGGCCCTGGTGGTATCGCAGCTGCTCCGGATCCCACAAGCTGTCGTGGACATGGTG GCGGGGGCCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGGGGAACT GGGCTAAGGTTTTGGTGATGCTACTCTTTGCCGGCGTCGACGGGCATACCCGCGT GTCAGGAGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTTAGCCCCGGG



Fig. 21L

TCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAACAGGACT GCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCTACAAAC ACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGACAA GTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGG CCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGT GCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTT TGGTGTCCCCACGTATAACTGGGGGGGCGAACGACTCGGATGTGCTGATTCTCAACAAC ACGCGGCCGCCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTCA CCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCAACACACCTTGA CCTGCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTC TGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTAC ACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACA GGGATAGATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGAGTGGCAGATACTGCC CTGTTCCTTCACCACCCTGCCGGCCCTATCCACCGGCCTGATCCACCTCCATCAGAAC ATCGTGGACGTGCAATACCTGTACGGTGTAGGGTCGGCGGTTGTCTCCCTTGTCATCA AATGGGAGTATGTCCTGTTGCTCTTCCTTCTCCTGGCAGACGCGCGCATCTGCGCCTGC TTATGGATGATGCTGCTGATAGCTCAAGCTGAGGCCGCCTTAGAGAACCTGGTGGTCC GCTGCCTGGTACATCAAGGGCAGGCTGGTCCCTGGTGCGGCATACGCCTTCTATGGCG TGTGGCCGCTGCTCCTGCTTCTGCTGGCCTTACCACCACGAGCTTATGCCTAGTAA



OD measured at 450 nm construct

Fraction	volume dilution	39 Type Ib	40 Type Ib	62 Type 3a	63 Type 5a
START FLOW THRO 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	23 ml 1/20 UGH 23 ml 1/20 0.4 ml 1/200	2.517 0.087 0.102 0.396 2.627 3 3 2.694 2.408 2.176 1.461 1.286 0.981 0.812 0.373 0.653 0.441 0.321 0.525 0.351	1.954 0.085 0.051 0.550 2.603 2.967 2.310 2.499 2.481 1.970 1.422 0.926 0.781 0.650 0.432 0.371 0.348 0.374 0.186 0.171	1.426 0.176 0.048 0.090 2.481 3 2.640 1.359 0.347 1.624 0.387 0.543 0.294 0.249 0.239 0.145 0.151 0.098 0.099 0.083	1.142 0.120 -0.050 0.067 2.372 2.694 2.154 1.561 1.390 0.865 0.604 0.519 0.294 0.199 0.299 0.199 0.106 0.108 0.090
19		0.192	0.164	0.084	0.087




Figure 24

			OD measured :: 450 nm construct				
Fraction	volume	dilution	39	40	62	63	
			Type	Type	Type	Type	
			1b	1b	3a	5a	
20	ا پ 250	1/200	0.072	0.130	0.096	0.05:	
21	Σου μ.	.,255	0.109	0.130	0.096	0.051	
22			0.279	0.249	0.064	0.052	
23			0.093	0.243	0.172	0.052	
24			0.080	0.157	0.438	0.054	
25			0.251	0.100	0.436 0.457	0.056	
25			3	1.649		0.048	
27				3	0.722 · 2.525	0.066	
28			3 3 3	3	2.525 3	0.889	
29			. 3	3 3	3 2.849	2.345 2.580	
30			2.227	1.921	1.424	1.333	
31			0.253	0.415	0.356	0.162	
32			0.071	0.172	0.356	0.162	
33			0.103	0.054	0.134	0.057	
34			0.045	0.045	0.030	0.051	
35			0.043	0.047	0.045	0.031	
36			0.045	0.045	0.049	0.040	
37			0.045	0.047	0.046	0.048	
38			0.046	0.048	0.047	0.057	
39			0.045	0.048	0.050	0.057	
40			0.046	0.049	0.048	0.049	




Fig. 25






Fig. 26




Fig.27






Fig.28

M 1 2 3 4 5 6 Fig. 29

67 kD -

45 kD -

29 kD -

18 kD -

14 kD -

Lane 1: Crude Lysate

Lane 2: Flow through Lentil Chromatography

Lane 3: Wash with EMPIGEN Lentil Chromatography

Lane 4: Eluate Lentil Chromatography

Lane 5: Flow through during concentration lentil eluate

Lane 6: Pool of Elafter Size Exclusion Chromatography





Fig. 30








Fig. 31B




SILVER STAIN OF PURIFIED E2



1. 30 mM IMIDAZOLE WASH NI-IMAC

2. 0.5 ug E2


Fig.33





No.	Ret. (mi)	Peak start (ml)	Peak end (ml)	Dur (ml)	Area (ml*mAU)	Height (mAU)
1	-0.45	-0.46	-0.43	0.04	0.0976	4.579
2	1.55	0.75	3.26	2.51	796.4167	889.377
3	3.27	3.26	3.31	0.05	0.0067	0.224
1	3.33	3.32	3.33	0.02	0.0002	0.018


Total number of detected peaks = 4 Total Area above baseline = 0.796522 ml*AU Total area in evaluated peaks = 0.796521 ml*AU Ratio peak area / total area = 0.999999 Total peak duration = 2.613583 ml

Fig. 34














Fig. 35A-6




Fig. 35A-7




Fig. 35A-8




Fig. 35B-1




Fig. 35B-2




Fig. 35B-3




Fig. 35B-4




Fig. 35B-5




Fig. 35B-6




Fig. 35B-7




Fig. 35B-8

Fig. 36A **E1 A**b





Fig. 36B **E2 Ab**






Fig. 38

Relative Map Positions of anti-E2 monoclonal antibodies




Fig.39 - 106.0 - 80.0 nш001 Glycopeptidase F (PNGase F) PARTIAL DEGLYCOSYLATION OF HCV E1 ENVELOPE PROTEIN nm0+ nm4 um4.0 um<u></u>40.0 umo Endoglycosidase H (Endo H) ոաց uma.0 ոա*ൻ*09 u49.0 u49 n*1*10



PARTIAL TREATMENT OF HCV E2/E2s ENVELOPE PROTEINS
BY PNGase F

	кDа	- 106	- 80	- 49.5	- 32.5
	Սայ				
41)	Umf.0			14.	
\ <u>\</u>	Umro.o				
Ϋ́	Uult			-94"	
E2s (vvHCV-41)	U41.0			湖多科	
E2	U410.0				
	-			11////	0-0-0
	Umt				
(Umt.0			1 3	
E2 (vvHCV-64)	Umto.o				
ÁHC	U41				
٤	Uut.o				
Ë	U410.0			ik jak	•••
	-	1	1	11 44	
	кDа	106	80	49.5 -	32.5

Fig. 40

Fig. 41 In Vitro Mutagenesis of HCV E1 glycoprotein






Fig. 42A In Vitro Mutagenesis of HCV E1 glycoprotein



First step of PCR amplification (Gly-# and Ovr-# primers)







Fig. 43 In Vitro Mutagenesis of HCV E1 glycoprotein






Fig. 44A




Fig.44B





Fig.45

Fig.46